<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Protamine sulfate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Protamine sulfate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Protamine sulfate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="12746" href="/d/html/12746.html" rel="external">see "Protamine sulfate: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="15561" href="/d/html/15561.html" rel="external">see "Protamine sulfate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7255805"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions: </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. Risk factors include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). Allergy to fish, previous vasectomy, and severe left ventricular dysfunction and abnormal preoperative pulmonary hemodynamics also may be risk factors. In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. Protamine sulfate should not be given when bleeding occurs without prior heparin use.  </p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F215167"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F215140"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The adult dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editor: Edith A Nutescu, PharmD, MS, FCCP.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b12c1c0e-6df9-470c-8243-90f6b288ebb7">Heparin neutralization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin neutralization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Following <i>IV </i>heparin administration:</b>
<b>IV:</b> Initial: Protamine dosage is determined by the amount of heparin administered; 1 mg of protamine neutralizes ~100 units of heparin; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); if aPTT remains elevated, may repeat 0.5 mg of protamine for every 100 units of heparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Because heparin concentration decreases rapidly after administration (half-life of heparin is ~60 to 90 minutes), adjust protamine dosage depending on duration of time since heparin administration. For example, if 2 hours has elapsed since a heparin overdose, administer half of the calculated initial protamine dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). If heparin was administered as a continuous IV infusion, calculate protamine dose based on heparin administered in the preceding 2 to 3 hours. For example, a patient receiving heparin 1,250 units/hour will require ~30 mg of protamine to neutralize heparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264','lexi-content-ref-26714677'])">Ref</a></span>). If patient is <b>not</b> bleeding, consider <b>not </b>administering protamine since risks may outweigh benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Cardiac surgery patients:</b> After cardiopulmonary bypass, repeat protamine doses of 25 to 50 mg may be given to reverse large doses of intraoperative heparin if activated clotting time (ACT) remains elevated or if heparin rebound is a concern; maximum total dose: 3 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kincaid.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kincaid.1'])">Ref</a></span>). For heparin rebound, may consider protamine 25 mg/hour continuous IV infusion for 6 hours following the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15282457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15282457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Following <i>SUBQ </i>heparin injection:</b>
<b>Note:</b> May consider protamine to neutralize prophylactic SUBQ doses of heparin when aPTT is significantly prolonged and patient has clinically significant bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-26714677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: Protamine dosage is determined by the amount of heparin administered; 1 mg of protamine neutralizes ~100 units of heparin; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Consider heparin absorption via SUBQ route when determining protamine dose. A portion of the protamine dose may be given IV over 10 minutes followed by the remaining portion as a continuous infusion over 8 to 16 hours (the expected absorption time of the SUBQ heparin dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caravati.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caravati.1'])">Ref</a></span>). If patient is <b>not</b> bleeding, consider <b>not</b> administering protamine since risks may outweigh benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07f434e0-f438-4285-a5b4-a7b839530b96">Low-molecular-weight heparin neutralization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low-molecular-weight heparin neutralization (off-label use): Note:</b> Protamine will not completely neutralize anti-factor Xa activity (maximum: ~60% to 75%). Excessive protamine doses may worsen bleeding (Lovenox prescribing information). Consider using in patients with clinically significant bleeding. If patient is <b>not</b> bleeding, consider <b>not</b> administering protamine since risks may outweigh benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Enoxaparin:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Enoxaparin administered in ≤8 hours:</i> Dose of protamine should equal the dose of enoxaparin administered. Administer 1 mg of protamine to neutralize 1 mg of enoxaparin; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lovenox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lovenox.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Enoxaparin administered &gt;8 hours to &lt;12 hours ago or if a second dose of protamine is required (eg, clinically significant bleeding continues):</i> Administer 0.5 mg of protamine for every 1 mg of enoxaparin administered; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lovenox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lovenox.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Enoxaparin administered ≥12 hours ago</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lovenox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lovenox.1'])">Ref</a></span>) <i>or if 3 to 5 half-lives have elapsed</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>)<i>:</i> Protamine administration may not be required.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Dalteparin, nadroparin, or tinzaparin:</b></i> 1 mg of protamine for every 100 anti-factor Xa units of low-molecular-weight heparin (LMWH) administered within the past 3 to 5 half-lives; administer by slow IV injection over ~10 minutes; maximum single dose: 50 mg. If clinically significant bleeding persists or patient has renal impairment, consider repeat dose of 0.5 mg of protamine for every 100 anti-factor Xa units of LMWH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677','lexi-content-ref-Fragmin.2','lexi-content-ref-Fraxiparine.1','lexi-content-ref-Innohep.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677','lexi-content-ref-Fragmin.2','lexi-content-ref-Fraxiparine.1','lexi-content-ref-Innohep.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990359"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987734"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F215141"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F215156"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12746" href="/d/html/12746.html" rel="external">see "Protamine sulfate: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mg of protamine sulfate neutralizes ~100 units of heparin or 1 mg of enoxaparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef66c58d-85f9-4026-957e-b063b8b6b3ca">Heparin neutralization/reversal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin (intravenous) neutralization/reversal:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: <b>Note:</b> Since heparin disappears rapidly from the circulation, the dose of protamine is adjusted based upon the time since heparin administration (see table). If given as a continuous IV infusion, only heparin given in the preceding 2 to 4 hours should be considered when administering protamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<table border="1" data-table-id="protam" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Heparin Neutralization/Reversal</b></caption>
<colgroup><col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Time Since Last Heparin Dose</p></th>
<th align="left">
<p style="text-indent:0em;">Dose of Protamine</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;30 minutes</p></td>
<td align="left">
<p style="text-indent:0em;">IV: 1 mg of protamine per 100 units of heparin; maximum dose: 50 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to 60 minutes</p></td>
<td align="left">
<p style="text-indent:0em;">IV: 0.5 to 0.75 mg of protamine per 100 units of heparin; maximum dose: 50 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">60 to 120 minutes</p></td>
<td align="left">
<p style="text-indent:0em;">IV: 0.375 to 0.5 mg of protamine per 100 units of heparin; maximum dose: 50 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;120 minutes</p></td>
<td align="left">
<p style="text-indent:0em;">IV: 0.25 to 0.375 mg of protamine per 100 units of heparin; maximum dose: 50 mg/dose</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a82e61cf-e6a6-490e-ae40-375e4c440cbf">Low molecular weight heparin neutralization/reversal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Low molecular weight heparin (LMWH) neutralization/reversal (enoxaparin, dalteparin):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Protamine will not completely neutralize the anti-Xa activity (maximum: ~60% to 75%). Protamine dosage is determined by the most recent dosage of LMWH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-Howland.1','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-Howland.1','lexi-content-ref-Park.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Enoxaparin (intravenous and subcutaneous) neutralization/reversal: </i>Limited data available: Dosing extrapolated from experience in adult patients:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV: Protamine dosage is determined by the most recent dosage and time of administration of enoxaparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lovenox.1','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lovenox.1','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Enoxaparin dose administered ≤8 hours:</i> IV: Dose of protamine should equal the dose of enoxaparin administered; therefore, 1 mg protamine sulfate neutralizes 1 mg of enoxaparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lovenox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lovenox.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Enoxaparin administered &gt;8 hours prior or if it has been determined that a second dose of protamine is required (eg, if aPTT measured 2 to 4 hours after the first dose remains prolonged or if bleeding continues):</i> IV: 0.5 mg protamine sulfate for every 1 mg enoxaparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Lovenox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Lovenox.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dalteparin (subcutaneous) neutralization/reversal: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV: 1 mg protamine for each 100 anti-Xa units of dalteparin; if aPTT prolonged 2 to 4 hours after first dose (or if bleeding continues), consider additional dose of 0.5 mg for each 100 anti-Xa units of dalteparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fragmin.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fragmin.2'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159514"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159515"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F215118"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized warm feeling</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Lassitude</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (McDonald 2020), circulatory shock, hypotension (McDonald 2020), right heart failure (right ventricular failure) (Pannu 2016), severe hypotension (Leung 2019, Pannu 2016), ventricular fibrillation (Leung 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Singla 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylactic shock, anaphylaxis, angioedema) (Doolan 1981, Roelofse 1991), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Noncardiogenic pulmonary edema (Kindler 1996), pulmonary complications (pulmonary vasoconstriction) (Lowenstein 1983), pulmonary hypertension (can be acute) (Pannu 2016)</p></div>
<div class="block coi drugH1Div" id="F215131"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to protamine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F215115"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Heparin rebound: Heparin rebound associated with anticoagulation and bleeding has been reported to occur occasionally; symptoms typically occur 8-9 hours after protamine administration, but may occur as long as 18 hours later.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity reactions: May cause hypersensitivity reaction in patients (have epinephrine 1 mg/mL  and resuscitation equipment available). <b>[US Boxed Warning]: Hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, pulmonary vasoconstriction, and pulmonary hypertension may occur. Risk factors for such events include use of high doses or overdose, repeated doses, previous protamine administration (including protamine-containing drugs), fish allergy, vasectomy, severe left ventricular dysfunction, and abnormal preoperative pulmonary hemodynamics.</b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Infusion reactions: Too rapid administration can cause severe hypotensive and anaphylactoid-like reactions.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiac surgery patients: May be ineffective in some patients following cardiac surgery despite adequate doses.</p></div>
<div class="block foc drugH1Div" id="F215125"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 25 mL)</p></div>
<div class="block geq drugH1Div" id="F215111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323746"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Protamine Sulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $2.68 - $3.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868070"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 25 mL)</p></div>
<div class="block adm drugH1Div" id="F215128"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV use only. Administer slow IVP (50 mg over 10 minutes). Rapid IV infusion causes hypotension; maximum of 50 mg in any 10-minute period.</p></div>
<div class="block admp drugH1Div" id="F52613727"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer undiluted (preferred) by slow IVP at a rate not to exceed 5 mg/minute (maximum rate: 50 mg in any 10-minute period); may be administered as diluted solution. <b>Note: </b>Rapid IV infusion causes hypotension.</p></div>
<div class="block use drugH1Div" id="F215126"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Heparin neutralization:</b> Treatment of heparin overdosage.</p></div>
<div class="block off-label drugH1Div" id="F25744618"><span class="drugH1">Use: Off-Label: Adult</span><p>Low-molecular-weight heparin neutralization</p></div>
<div class="block mst drugH1Div" id="F215175"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Protamine may be confused with ProAmatine, Protonix, Protopam</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299956"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222615"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13801118"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Protamine sulfate may be used during delivery to reduce the risk of bleeding following maternal use of heparin or low molecular weight heparin (LMWH) (Bates,  2012).</p></div>
<div class="block brc drugH1Div" id="F20618193"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if protamine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering protamine to nursing women.</p></div>
<div class="block mop drugH1Div" id="F215123"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Coagulation test, aPTT or ACT, cardiac monitor and blood pressure monitor required during administration</p></div>
<div class="block pha drugH1Div" id="F215114"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Protamine, a highly alkaline protein molecule with a large positive charge, has weak anticoagulant activity when administered alone. When protamine is given in the presence of heparin (strongly acidic and negatively charged), a stable salt is formed and the anticoagulant activity of both drugs is nullified (Pai 2012). In the presence of LMWH, protamine incompletely reverses the anti-factor Xa activity of LMWH (Makris 2000; Massonnet-Castel 1986; Racanelli 1985).</p></div>
<div class="block phk drugH1Div" id="F215130"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: Heparin neutralization: ~5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~7 minutes </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038788"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Protamina</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Protamine | Protamine sulfaat leo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulfat leo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Protamin | Protamin sulfate</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Protamina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Protamina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamin | Protamin sulphate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate | Sulfiprotam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Protamina leo | Protamina rovi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Protamiinisulfaatti Leo Pharma | Protamin | Protamini sulfas | Protaminsulfat Leo pharma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamine choay</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamin sulphate | Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Prosulf</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Neutrahep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Protamina | Protamina solfato | Protamina solfato leo pharma</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Novo protamin sulfate | Novo protamine sulfate | Protami.sulf.ajino</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Urota</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Prosulf</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulfate | Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Protamine Sulfaat</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulphate | Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Protamine choay</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Prosulf | Protamine sulphate | Taminfate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulfaat LEO Pharma</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Protamina sulfato</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Neutrahep | Prosulf | Protamin sulfat | Protamine | Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Protamina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Prosulf</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Pamintu</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Protagem | Protamin | Protamin Ferein | Protamine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulfat | Protaminsulfat Leo pharma | Protaminsulfat paranova</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulfat | Protaminijev sulfat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Protamin sulfate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Prosulf</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pamintu | Promin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Denpru | Protamina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Protamine sulphate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2091796">
<a name="2091796"></a>Aren C, “Heparin and Protamine Therapy,” <i>Semin Thorac Cardiovasc Surg</i>, 1990, 2(4):364-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2091796/pubmed" id="2091796" target="_blank">2091796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315276">
<a name="22315276"></a>Bates SM, Greer IA, Middeldorp S, et al. “VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315276/pubmed" id="22315276" target="_blank">22315276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caravati.1">
<a name="Caravati.1"></a>Caravati EM. Protamine sulfate. <i>Medical Toxicology</i>. 3rd ed. Dart RC, ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004;243-244.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15186641">
<a name="15186641"></a>Chawla LS, Moore G, Seneff MG. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. <i>Obesity Surg</i>. 2004;14(5):695-698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/15186641/pubmed" id="15186641" target="_blank">15186641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7258612">
<a name="7258612"></a>Doolan L, McKenzie I, Krafchek J, Parsons B, Buxton B. Protamine sulphate hypersensitivity. <i>Anaesth Intensive Care</i>. 1981;9(2):147-149. doi:10.1097/00132586-198206000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/7258612/pubmed" id="7258612" target="_blank">7258612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21207349">
<a name="21207349"></a>Flaherty ML, “Anticoagulant-Associated Intracerebral Hemorrhage,” <i>Semin Neuro</i>, 2010, 30(5):565-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/21207349/pubmed" id="21207349" target="_blank">21207349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fragmin.1">
<a name="Fragmin.1"></a>Fragmin (dalteparin) [prescribing information]. New York, NY: Pfizer Inc; October 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fragmin.2">
<a name="Fragmin.2"></a>Fragmin (dalteparin) [prescribing information]. New York, NY: Pfizer Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fraxiparine.1">
<a name="Fraxiparine.1"></a>Fraxiparine and Fraxiparine Forte (nadroparin calcium) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46. doi:10.1007/s12028-015-0222-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2 suppl):e24S‐e43S. doi:10.1378/chest.11-2291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579034">
<a name="35579034"></a>Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/35579034/pubmed" id="35579034" target="_blank">35579034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3883848">
<a name="3883848"></a>Horrow JC, “Protamine: A Review of Its Toxicity,” <i>Anesth Analg</i>, 1985, 64(3):348-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/3883848/pubmed" id="3883848" target="_blank">3883848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland MA, Nelson L, Lewin NA, Silas WS, Goldfrank LR, Hoffman R. Protamine. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. New York, NY: McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Innohep.1">
<a name="Innohep.1"></a>Innohep (tinzaparin) [prescribing information]. Parsippany, NJ; LEO Pharma Inc: May 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4122234">
<a name="4122234"></a>Jaques LB, “Protamine - Antagonist to Heparin,” <i>Can Med Assoc J</i>, 1973, 108(10):1291-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/4122234/pubmed" id="4122234" target="_blank">4122234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kincaid.1">
<a name="Kincaid.1"></a>Kincaid EH, Hammon JW. Cardiopulmonary Bypass. In: Yuh DD, Varicella LA, Yang SC, Doty JR. eds. <i>Johns Hopkins Textbook of Cardiothoracic Surgery.</i> 2nd ed. New York, NY: McGraw-Hill; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8817145">
<a name="8817145"></a>Kindler C, Bircher A, Stulz P. Protamine-induced fulminating non-cardiogenic pulmonary edema following cardiopulmonary bypass. <i>Eur J Cardiothorac Surg</i>. 1996;10(6):463-466. doi:10.1016/s1010-7940(96)80117-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/8817145/pubmed" id="8817145" target="_blank">8817145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7949674">
<a name="7949674"></a>Kondo NI, Maddi R, Ewenstein BM, et al, “Anticoagulation and Hemostasis in Cardiac Surgical Patients,” <i>J Card Surg</i>, 1994, 9(4):443-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/7949674/pubmed" id="7949674" target="_blank">7949674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30649275">
<a name="30649275"></a>Leung LWM, Gallagher MM, Evranos B, et al. Cardiac arrest following protamine administration: a case series. <i>Europace</i>. 2019;21(6):886-892. doi:10.1093/europace/euy288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/30649275/pubmed" id="30649275" target="_blank">30649275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2663545">
<a name="2663545"></a>Lindblad B, “Protamine Sulfate: A Review of Its Effects - Hypersensitivity and Toxicity,” <i>Eur J Vasc Surg</i>, 1989, 3(3):195-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2663545/pubmed" id="2663545" target="_blank">2663545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2827339">
<a name="2827339"></a>Lindblad B, Borgström A, Wakefield TW, Whitehouse WM Jr, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. <i>Thromb Res</i>. 1987;48(1):31-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/2827339/pubmed" id="2827339" target="_blank">2827339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lovenox.1">
<a name="Lovenox.1"></a>Lovenox (enoxaparin) [prescribing information]. Bridgewater, NJ; Sanofi-Aventis US LLC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lovenox.2">
<a name="Lovenox.2"></a>Lovenox (enoxaparin sodium) [prescribing information]. Bridgewater, NJ; Sanofi-Aventis US LLC; April 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lovenox.3">
<a name="Lovenox.3"></a>Lovenox (enoxaparin sodium injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6638558">
<a name="6638558"></a>Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. <i>Anesthesiology</i>. 1983;59(5):470-473. doi:10.1097/00000542-198311000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/6638558/pubmed" id="6638558" target="_blank">6638558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10858037">
<a name="10858037"></a>Makris M, Hough RE, and Kitchen S, et al, “Poor Reversal of Low Molecular Weight Heparin by Protamine,” <i>Br J Haematol</i>, 2000, 108(4): 884-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/10858037/pubmed" id="10858037" target="_blank">10858037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3710291">
<a name="3710291"></a>Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. <i>Haemostasis</i>. 1986;16(2):139-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/3710291/pubmed" id="3710291" target="_blank">3710291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33209517">
<a name="33209517"></a>McDonald BA, Buda KG, Hall JR 2nd, Carlson MD, Kempainen R. Protamine-induced bradycardic arrest in a diabetic patient. <i>Cureus</i>. 2020;12(10):e10955. doi:10.7759/cureus.10955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/33209517/pubmed" id="33209517" target="_blank">33209517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142345">
<a name="20142345"></a>Moganasundram S, Hunt BJ, Sykes K, et al, "The Relationship Among Thromboelastography, Hemostatic Variables, and Bleeding After Cardiopulmonary Bypass Surgery in Children," <i>Anesth Analg</i>, 2010, 110(4):995-1002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/20142345/pubmed" id="20142345" target="_blank">20142345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan AK, Goldenberg NA, et al; American College of Chest Physicians. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in <i>Chest</i>. 2014;146(5):1422 and <i>Chest</i>. 2014;146(6):1694]. <i>Chest</i>. 2012;141(2 suppl):e737S-801S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22566228">
<a name="22566228"></a>Pai M, Crowther MA. Neutralization of heparin activity. <i>Handb Exp Pharmacol</i>. 2012;(207):265-277. doi:10.1007/978-3-642-23056-1_1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/22566228/pubmed" id="22566228" target="_blank">22566228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27076733">
<a name="27076733"></a>Pannu BS, Sanghavi DK, Guru PK, Reddy DR, Iyer VN. Fatal right ventricular failure and pulmonary hypertension after protamine administration during cardiac transplantation. <i>Indian J Crit Care Med</i>. 2016;20(3):185-187. doi:10.4103/0972-5229.178185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/27076733/pubmed" id="27076733" target="_blank">27076733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Protamine.1">
<a name="Protamine.1"></a>Protamine [prescribing information]. Lake Zurich, IL: Fresenius Kabi; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4035365">
<a name="4035365"></a>Racanelli A, Fareed J, Walenga JM, Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. <i>Semin Thromb Hemost</i>. 1985;11(2):176-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/4035365/pubmed" id="4035365" target="_blank">4035365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1814251">
<a name="1814251"></a>Roelofse JA, van der Bijl P. An anaphylactic reaction to protamine sulfate. <i>Anesth Prog</i>. 1991;38(3):99-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/1814251/pubmed" id="1814251" target="_blank">1814251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23384227">
<a name="23384227"></a>Singla A, Sullivan MJ, Lee G, et al. Protamine-induced immune thrombocytopenia. <i>Transfusion</i>. 2013;53(10):2158-2163. doi:10.1111/trf.12112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/23384227/pubmed" id="23384227" target="_blank">23384227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15282457">
<a name="15282457"></a>Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? <i>J Thorac Cardiovasc Surg</i>. 2004;128(2):211-219. doi:10.1016/j.jtcvs.2003.12.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/15282457/pubmed" id="15282457" target="_blank">15282457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079003">
<a name="17079003"></a>Wiernikowski JT, Chan A, and Lo G, "Reversal of Anti-Thrombin Activity Using Protamine Sulfate. Experience in a Neonate With a 10-fold Overdose of Enoxaparin," <i>Thromb Res</i>, 2007, 120(2):303-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/protamine-sulfate-drug-information/abstract-text/17079003/pubmed" id="17079003" target="_blank">17079003</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9831 Version 174.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
